GSK, european union and Endometrial Cancer
Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...
The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...
GSK PLC GSK shares inched down 0.22% to £13.56 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 0.04% to 8,545.13. Supported ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback